|
Secondary malignant neoplasm of colon and/or rectum
|
0.070 |
Biomarker
|
disease |
BEFREE |
To evaluate the efficacy and safety of S-1 (containing a DPD inhibitor) and raltitrexed (a TS inhibitor) for refractory mCRC, a one-center, single-arm, prospective phase II trial was conducted.
|
30651398 |
2019 |
|
Esophageal Neoplasms
|
0.050 |
PosttranslationalModification
|
group |
BEFREE |
In an attempt to determine the levels of LINC00261 related to the esophageal cancer cell resistance to 5-FU and to identify the interaction between the levels of LINC00261 and methylation of the DYPD promoter, esophageal cancer cells TE-1 and -5 were prepared, in which LINC00261 and the 5-FU-resistant TE-1 and -5 cells were overexpressed.
|
30226808 |
2019 |
|
Esophageal carcinoma
|
0.050 |
PosttranslationalModification
|
disease |
BEFREE |
In an attempt to determine the levels of LINC00261 related to the esophageal cancer cell resistance to 5-FU and to identify the interaction between the levels of LINC00261 and methylation of the DYPD promoter, esophageal cancer cells TE-1 and -5 were prepared, in which LINC00261 and the 5-FU-resistant TE-1 and -5 cells were overexpressed.
|
30226808 |
2019 |
|
Malignant neoplasm of esophagus
|
0.050 |
PosttranslationalModification
|
disease |
BEFREE |
In an attempt to determine the levels of LINC00261 related to the esophageal cancer cell resistance to 5-FU and to identify the interaction between the levels of LINC00261 and methylation of the DYPD promoter, esophageal cancer cells TE-1 and -5 were prepared, in which LINC00261 and the 5-FU-resistant TE-1 and -5 cells were overexpressed.
|
30226808 |
2019 |
|
Septicemia
|
0.030 |
Biomarker
|
disease |
BEFREE |
To evaluate the effect of direct hemoperfusion with polymyxin B immobilized cartridge (DHP-PMX) on meropenem pharmacokinetics in critically ill patients with sepsis requiring continuous venovenous hemofiltration (CVVH).
|
30769293 |
2019 |
|
Sepsis
|
0.030 |
Biomarker
|
disease |
BEFREE |
To evaluate the effect of direct hemoperfusion with polymyxin B immobilized cartridge (DHP-PMX) on meropenem pharmacokinetics in critically ill patients with sepsis requiring continuous venovenous hemofiltration (CVVH).
|
30769293 |
2019 |
|
Senile cardiac amyloidosis
|
0.030 |
Biomarker
|
disease |
BEFREE |
Prevalence of Positive <sup>99 m</sup>Tc-DPD Scintigraphy as an Indicator of the Prevalence of Wild-type Transthyretin Amyloidosis in the Elderly.
|
31019172 |
2019 |
|
Post-Traumatic Stress Disorder
|
0.020 |
Biomarker
|
disease |
BEFREE |
A PTSD-related decrease in the 5α-DHP to progesterone ratio indicated a block in allopregnanolone synthesis at 5α-reductase.
|
30529908 |
2019 |
|
Thrombocytopenia
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
DPYD*9A carries were found to be at higher risk for HFS, diarrhoea and thrombocytopenia when compared to patients with wild allele.
|
31653159 |
2019 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.010 |
Biomarker
|
disease |
BEFREE |
Using DHP, a larger negative impact related to type 2 diabetes mellitus is found in those with lower educational level, female and younger (20-39 years) or older (60-79 years) subjects.
|
30799197 |
2019 |
|
Diabetic Nephropathy
|
0.010 |
Biomarker
|
disease |
BEFREE |
<b>Conclusion:</b> Non-DHP CCBs may be a reasonable therapeutic option for patients with diabetic kidney disease and persistent proteinuria despite maximum doses of ACE inhibitors or ARBs.
|
30966785 |
2019 |
|
Fibrosarcoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Moreover, we have established that increasing the length of the alkyl chain at the quaternised nitrogen of the 4-(<i>N</i>-alkylpyridinium)-1,4-DHP molecule or the introduction of propargyl moieties in the 1,4-DHP molecule significantly influences the cytotoxicity on HT-1080 (human fibrosarcoma) and MH-22A (mouse hepatocarcinoma) cell lines, as well as the estimated basal cytotoxicity.
|
30871041 |
2019 |
|
Left Ventricular Hypertrophy
|
0.010 |
Biomarker
|
disease |
BEFREE |
Transthoracic echocardiography was used to assess left ventricular hypertrophy (LVH), as well as systolic and diastolic function.A positive DPD scan was observed in only six patients (0.06%).
|
31019172 |
2019 |
|
Carcinoma breast stage IV
|
0.010 |
Biomarker
|
disease |
BEFREE |
We reviewed medical records for consecutive patients with mBC who underwent DPYD genotyping before commencing capecitabine between December 2014 and December 2017.
|
30746637 |
2019 |
|
Adult Fibrosarcoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Moreover, we have established that increasing the length of the alkyl chain at the quaternised nitrogen of the 4-(<i>N</i>-alkylpyridinium)-1,4-DHP molecule or the introduction of propargyl moieties in the 1,4-DHP molecule significantly influences the cytotoxicity on HT-1080 (human fibrosarcoma) and MH-22A (mouse hepatocarcinoma) cell lines, as well as the estimated basal cytotoxicity.
|
30871041 |
2019 |
|
Cancer of Urinary Tract
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
5-Fluorouracil-based adjuvant chemotherapy improves the clinical outcomes of patients with lymphovascular invasion of upper urinary tract cancer and low expression of dihydropyrimidine dehydrogenase.
|
30944635 |
2019 |
|
AMYLOIDOSIS, HEREDITARY, TRANSTHYRETIN-RELATED
|
0.010 |
Biomarker
|
disease |
BEFREE |
Prevalence of Positive <sup>99 m</sup>Tc-DPD Scintigraphy as an Indicator of the Prevalence of Wild-type Transthyretin Amyloidosis in the Elderly.
|
31019172 |
2019 |
|
PARKINSON DISEASE, LATE-ONSET
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Five studies compared BDNF in serum of PD patients versus healthy controls (HC) and 3 studies provided BDNF levels in sera of non-depressed and depressed PD patients (NDPD and DPD).
|
30296429 |
2019 |
|
Transthyretin cardiac amyloidosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Either 99mTechnetium diphosphonate (Tc-DPD) or pyrophosphate (Tc-PYP) scintigraphy plays a relevant role in diagnosing transthyretin cardiac amyloidosis (CA), and labeled radiotracers have been extensively studied in diagnosing CA.
|
28537040 |
2019 |
|
Dihydropyrimidine Dehydrogenase Deficiency
|
0.800 |
AlteredExpression
|
disease |
BEFREE |
The steady-state concentration of 5-FU administered through the hepatic artery was achieved after 15 h. DPD levels were analysed through determining the ratio of plasma uracil (U) and dihydrouracil (UH2) by HPLC, and the results indicated a mild DPD deficiency in the patients with HCC.
|
29725440 |
2018 |
|
Dihydropyrimidine Dehydrogenase Deficiency
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Genome sequencing reveals a novel genetic mechanism underlying dihydropyrimidine dehydrogenase deficiency: A novel missense variant c.1700G>A and a large intragenic inversion in DPYD spanning intron 8 to intron 12.
|
29691939 |
2018 |
|
Dihydropyrimidine Dehydrogenase Deficiency
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Capecitabine-based treatment of a patient with a novel DPYD genotype and complete dihydropyrimidine dehydrogenase deficiency.
|
28929491 |
2018 |
|
Schizophrenia
|
0.410 |
GeneticVariation
|
disease |
GWASCAT |
Common schizophrenia alleles are enriched in mutation-intolerant genes and in regions under strong background selection.
|
29483656 |
2018 |
|
Malignant Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis.
|
30348537 |
2018 |
|
Colorectal Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Immunohistochemical localization of 5-FU metabolic enzymes (TS, MTHFR, DPYD, and TP) was evaluated in 143 untreated patients with colorectal cancer; their prognostic and predictive values were also evaluated.
|
29799355 |
2018 |